Cancer Vaccine development for Hepatocellular Carcinoma

What is HEPAVAC ?

HEPAVAC aims to develop a highly innovative, novel cancer vaccine approach to address the high unmet medical need of hepatocellular carcinoma (HCC) patients. HCC is the most common primary liver malignancy accounting for about 6% of all new cancer cases diagnosed worldwide(nearly 750,000 new cases/year), and is the third and the fifth leading cause of death from cancer globally in men and women, respectively. Given the current lack of available effective treatments, the overall prognosis for patients with HCC is poor with a dismal 5-year survival rate of approximately 5-6%, making the disease a highly important and relevant target for the development of innovative and novel therapies. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool.

Recent News


HEPAVAC consortium presents at CIMT 2015

Welcome to HEPAVAC’s presentations at CIMT Annual Meeting 2015 (May 11– May 13) in Mainz, Germany:   Monday, May 17.00 – 19.00,... Read More →

HEPAVAC annual meeting

The first annual meeting of the HEPAVAC collaborative project took place last 15th and 16th October in Tuebingen, co-hosted by... Read More →

Project’s details

Call Identifier: FP7-HEALTH-2013-INNOVATION-1
Activity code: HEALTH.2013.2.4.1-2: Strengthening the cancer patient’s immune system
Funding Scheme: Collaborative project
Project number: 602893
Total funding: 5,996,110.80 Euros
Duration: 60 Months
Starting date:1st September 2013

Back to Top